Page last updated: 2024-08-24

gemcitabine and cabozantinib

gemcitabine has been researched along with cabozantinib in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Dosch, J; Hynes, M; Li, C; Pasca di Magliano, M; Sarkar, B; Simeone, DM; Welling, TH; Wu, JJ	1
Giese, N; Giese, T; Gladkich, J; Hage, C; Herr, I; Labsch, S; Mattern, J; Nwaeburu, C; Rausch, V; Schönsiegel, F	1
Camphausen, K; Griffith, KA; Kim, EJ; Ruch, JM; Sahai, V; Savage, JE; Simeone, DM; Zalupski, MM; Zhen, DB	1

Trials

1 trial(s) available for gemcitabine and cabozantinib

Article	Year
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Investigational new drugs, 2016, Volume: 34, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Pyridines; Survival Rate	2016

Article

Year

A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.

Investigational new drugs, 2016, Volume: 34, Issue:6

Topics: Adenocarcinoma; Adult; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Pyridines; Survival Rate

2016

Other Studies

3 other study(ies) available for gemcitabine and cabozantinib

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology, 2011, Volume: 141, Issue:6 Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Therapy, Combination; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines	2011
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell death & disease, 2013, May-09, Volume: 4 Topics: Anilides; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines; Signal Transduction; SOXB1 Transcription Factors; Stem Cells	2013